


## PHARMACEUTICAL 2022

## Transcode Therapeutics Inc. Rank 115 of 466





## PHARMACEUTICAL 2022



## Transcode Therapeutics Inc. Rank 115 of 466

The relative strengths and weaknesses of Transcode Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Transcode Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 82% points. The greatest weakness of Transcode Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 222%, being 144% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	22,732
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,534
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-692
Other Revenues	0
Property and Equipment	206
Research and Development	2,754
Selling, General and Administrative Expense	3,397

Output Variable	Value in 1000 USD
Assets	22,938
Liabilities	2,534
Expenses	6,151
Revenues	0
Stockholders Equity	20,404
Net Income	-6,843
Comprehensive Net Income	-6,843
Economic Capital Ratio	222%

